Figure 5 | Hypertension Research

Figure 5

From: Simvastatin prevents large blood pressure variability induced aggravation of cardiac hypertrophy in hypertensive rats by inhibiting RhoA/Ras–ERK pathways

Figure 5

a, Effects of SAD and simva on RhoA (left) and Ras (right) activity levels. Relative fluorescence unit (RFU). Bar=1 × s.d. (n=10). b, Effects of SAD and simva on ERK1/2 activity levels. Top, representative immunoblots for protein expression (ERK1/2) and phosphorylation level of ERK1/2 (pERK1/2). Bottom, pooled data of the effects on ERK phosphorylation levels. The density of the phosphorylated p42 band was normalized to that of p42 in each sample (pERK/ERK). Bar=1 × s.d. (n=6). *P<0.05 vs. Sham+vehicle; δP<0.05 and δδP<0.01 vs. Sham+Simva; †P<0.05 and ††P<0.01 vs. SAD+vehicle.

Back to article page